{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:47:52Z","timestamp":1794354472625,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neo.2024.101056","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T15:26:25Z","timestamp":1726241185000},"page":"101056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6259-3054","authenticated-orcid":false,"given":"Pamela N.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina S.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-3705","authenticated-orcid":false,"given":"Felicia","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonagh","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pollara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-0787","authenticated-orcid":false,"given":"Mark J.","family":"Cantwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Berchuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Antonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-9120","authenticated-orcid":false,"given":"Rebecca A.","family":"Previs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2024.101056_bib0001","unstructured":"Cancer Stat Facts: Ovarian Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"10.1016\/j.neo.2024.101056_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0003","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0004","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Van Driel","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0006","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-Cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2024.101056_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0008","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0009","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0011","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0012","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0013","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0014","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0015","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized Phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neo.2024.101056_bib0017","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neo.2024.101056_bib0018","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","article-title":"Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells","volume":"40","author":"Anadon","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2024.101056_bib0019","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0021","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2024.101056_bib0022","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2024.101056_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s42003-020-0873-9","article-title":"Pan-cancer molecular analysis of the RB tumor suppressor pathway","volume":"3","author":"Knudsen","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.neo.2024.101056_bib0024","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1413","article-title":"Helping the CD8(+) T-cell response","volume":"4","author":"Bevan","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neo.2024.101056_bib0026","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1084\/jem.20031591","article-title":"Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN","volume":"199","author":"Ahonen","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0027","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.1158\/0008-5472.CAN-09-2019","article-title":"Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects","volume":"69","author":"Cho","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.101056_bib0028","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT103","article-title":"A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity","volume":"83","author":"Saltos","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.101056_bib0029","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/2326-6066.CIR-22-0927","article-title":"Combination IFNbeta and Membrane-Stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic t-cell immunity","volume":"11","author":"Zheng","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.neo.2024.101056_bib0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/978-1-0716-0795-4_30","article-title":"The quantification of antigen-specific T Cells by IFN-gamma ELISpot","volume":"2183","author":"Akache","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neo.2024.101056_bib0031","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1038\/onc.2013.321","article-title":"Epithelial ovarian cancer experimental models","volume":"33","author":"Lengyel","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2024.101056_bib0032","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2024.101056_bib0033","article-title":"A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)","volume":"8","author":"Stewart","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2024.101056_bib0034","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.3390\/cancers13174318","article-title":"Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response","volume":"13","author":"Rickard","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2024.101056_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.neo.2024.101056_bib0036","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.neo.2024.101056_bib0037","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.neo.2024.101056_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.neo.2024.101056_bib0039","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/08830185.2012.698337","article-title":"T-cell-independent antitumor effects of CD40 ligation","volume":"31","author":"Rakhmilevich","year":"2012","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.neo.2024.101056_bib0040","first-page":"14","article-title":"Development and characterization of a luciferase labeled, syngeneic murine model of ovarian cancer","author":"Russell","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2024.101056_bib0041","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.neo.2024.101056_bib0042","article-title":"A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS One"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T23:07:47Z","timestamp":1729206467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"alternative-id":["S1476558624000976"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101056","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101056"}}